Private Equity Firm to Acquire SeraCare for $82M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SeraCare Life Sciences has signed a definitive agreement to be acquired by private equity firm Linden Capital Partners for $4 per share, or around $82 million.

The purchase price represents a 25 percent premium to the 30-day volume-weighted average stock price of SeraCare. The Milford, Mass.-based firm, which makes life sciences tools including molecular biomarkers and controls, would become a private company, wholly owned by Linden.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.